vTv Therapeutics Inc. (VTVT) Stock Price Up 6.9%
vTv Therapeutics Inc. (NASDAQ:VTVT)’s share price rose 6.9% on Wednesday . The company traded as high as $6.10 and last traded at $5.88, with a volume of 92,842 shares. The stock had previously closed at $5.50.
Separately, Zacks Investment Research downgraded vTv Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 4th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $16.80.
The stock’s market cap is $56.69 million. The company’s 50-day moving average is $5.75 and its 200-day moving average is $5.85.
vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings results on Thursday, May 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.12. Analysts expect that vTv Therapeutics Inc. will post ($2.63) EPS for the current year.
In other vTv Therapeutics news, Director Paul G. Savas bought 6,000 shares of the firm’s stock in a transaction on Friday, May 27th. The stock was acquired at an average price of $5.67 per share, with a total value of $34,020.00. Following the completion of the purchase, the director now owns 58,781 shares of the company’s stock, valued at $333,288.27. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.